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Global Perspective Approach to Multiple Sclerosis:
Abstract
Afflicting 1 in 1000 people in Western countries, Multiple Sclerosis (MS) 
is the leading nontraumatic cause of neurologic disability in young adults.1 The 
experience one person will have with the illness will be different from the next, therefore 
MS will never have a “one size fits all” treatment strategy. MS is a demyelination 
disease of the central nervous system, presents with a wide spectrum of neurologic 
symptoms. Physical Therapy can help people with MS manage their symptoms and 
improve impairments. Physical Therapists working with people with MS need to be fully 
aware of the “Big Picture” of MS, not just the view as a therapist but also the view as 
patient with MS, the Doctor treating MS, family member of person with MS, friend of 
person with MS, other therapy field perspectives, etc. The physical therapist can make a 
substantial difference in the life of a person with MS if they hold a global perspective of 
the disease and its victims.
1Afflicting 1 in 1000 people in Western countries, Multiple Sclerosis (MS) is the 
leading nontraumatic cause of neurologic disability in young adults.1 The experience one 
person will have with the illness will be different from the next, therefore MS will never 
have a “one size fits all” treatment strategy. MS is a demyelination disease of the central 
nervous system, presents with a wide spectrum of neurologic symptoms.
There are more women with MS than men by a ratio of about 1.4 to 1.0. MS is 
rarely found amongst non-white populations such as Asians and Africans, but is 
commonly found amongst Caucasians, and especially those with northern European 
ancestry. It is also found more commonly in temperate areas compared to tropical areas. 
The prevalence of MS tends to increase with movement away from the equator in both 
hemispheres. The highest rates in the world are found in Canada, northern United States, 
northern Europe, Australia, and New Zealand. This report will outline the most common 
symptoms, types of MS, quality of life (QOL), staging of symptoms, treatment of 
symptoms, factors affecting the patient/Physical Therapist relationship, factors affecting 
available treatments, and the importance of participation and mobility in life.
Amongst visual disturbances, cerebellar symptoms, paresis, bowel dysfunction, 
bladder dysfunction, sensory loss and cognitive impairment, excessive fatigue is one of 
the most disturbing symptoms.3 While the cause of MS is still not known, extensive 
scientific research indicates that a combination of several factors may be involved. The 
major scientific theories about the causes of MS include the following: immunologic, 
environmental, infectious agent, and genetic.4
2It is now generally accepted that MS involves an autoimmune process—an 
abnormal immune response directed against the Central Nervous System (CNS); the 
brain, spinal cord and optic nerves. The exact antigen, or target that the immune cells are 
sensitized to attack, remains unknown. In recent years, however, researchers have been 
able to identify which immune cells are mounting the attack, some of the factors that 
cause them to attack, and some of the sites, or receptors, on the attacking cells that appear 
to be attracted to the myelin to begin the destructive process. The destruction of myelin— 
the fatty sheath that surrounds and insulates the nerve fibers—as well as damage to the 
nerve fibers themselves, cause the nerve impulses to be slowed or halted and produce the 
symptoms of MS. Some nerve fibers, known as axons, never recover from the effects of 
demyelination and become permanently damaged, known as “axonal damage”.5 
Researchers are looking for highly specific immune-modulating therapies to stop this 
abnormal immune response without harming normal immune functions.
Migration patterns and epidemiologic studies—those that take into account 
variations in geography, socioeconomics, genetics, and other factors—have shown that 
people who are bom in an area of the world with a high risk of MS and then move to an 
area with a lower risk before the age of 15, acquire the risk of their new home. Such data 
suggest that exposure to some environmental agent that occurs before puberty may 
predispose a person to develop MS later on. MS occurs more frequently in areas that are 
farther from the equator. Some scientists think the reason may have something to do with 
vitamin D, which the human body produces naturally when the skin is exposed to
3sunlight. People who live closer to the equator are exposed to greater amounts of sunlight 
year-round. As a result, they tend to have higher levels of naturally-produced vitamin D, 
which is thought to have a beneficial impact on immune function and may help protect 
against autoimmune diseases like MS.1 The possible relationship between MS and 
sunlight exposure is currently being looked at in a Society-funded epidemiological study 
in Australia.
Since viruses are well recognized as causes of demyelination and inflammation, it 
is possible that a virus or other infectious agent is the triggering factor in MS. Initial 
exposure to many viruses, bacteria and other microbes occur during childhood; more 
than a dozen viruses and bacteria, including measles, canine distemper, human herpes 
virus-6, Epstein-Barr, and Chlamydia pneumonia have been or are being investigated to 
determine if they are involved in the development of MS. As of now none of these have 
been definitively proven to trigger MS.
While MS is not hereditary in a strict sense, having a first-degree relative such as 
a parent or sibling with MS increases an individual's risk of developing the disease. This 
increased risk is several-fold above the risk for the general population. Some studies 
show a higher prevalence of certain genes in populations with higher rates of MS. 
Common genetic factors have also been found in some families where there is more than 
one person with MS. Some researchers theorize that MS develops because a person is 
bom with a genetic predisposition to react to some environmental agent that triggers an 
autoimmune response upon exposure.4
Figure 2 7 - 6 ,  World map showing the relative incidence of multiple sclerosis. Areas of greatest risk are in the northern latitudes. 












5Although MS is a chronic progressive disease, the disease may take a variety o f 
courses. Listed in severity, the following courses have been identified as follows. A 
benign course effects approximately 20% of patients and is characterized by an abrupt 
onset with one or a few exacerbations and complete or nearly complete remissions.
These persons experience little or no permanent disability and remain relatively 
symptom-free. An exacerbating-remitting or relapsing course will affect approximately 
20% to 30% with the course being similar to a benign course.
These symptoms, however, will reoccur between long stable periods and the 
disease may not progress to increasing levels of disability. A remitting or relapsing- 
progressive course affects 30% to 40%. These persons have acute relapses, but 
subsequently develop a progressive worsening of impairments and disability. A primary 
chronic or progressive course is found in 20% of persons with MS with the most common 
clinical presentation of primary progressive MS is myelopathy, a gradual progressive 
weakening and wasting of muscle, and is typically seen in persons with onset beginning 
over the age of 40 years.1 Primary progressive MS may present in other ways, including 
a progressive cerebella disorder or dementia.6
6The following diagram was taken from source 7.
sfceape® www.medscape .corn
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7Each individual’s brain stem appears to have a different threshold for producing 
symptoms and signs reflecting the affected regions of the CNS. This threshold, or the 
capacity of the individual’s brain to adapt to the lesions will determine the severity of the 
clinical manifestations. Usually persons with early MS predominantly have one of the 
initial syndromes which can be categorized as corticospinal, brainstem, cerebella, or 
cerebral. The following symptoms can occur in isolation or in combination. More than 
one syndrome may be found in come individuals. The corticospinal syndrome is the 
most common, involving the corticospinal tracts and the dorsal column. Stiffness, 
slowness, and weakness are components of corticospinal tract impairments.6 Spasticity is 
an extremely common problem in patients with MS, occurring in 90% of cases. 
Associated signs of upper motor neuron syndrome may include clonus, spontaneous 
spasm, positive Babinski’s sign, and loss of precise autonomic control.7
The Brainstem syndrome reflects lesions of cranial nerves III through XII at the 
root, nuclear, or bulbar level. Common brainstem symptoms are gaze palsies, the loss of 
active control of eye movement; nystagmus, involving involuntary rhythmic tremor of the 
eye; and dysarthria, abnormal speech resulting from poor control of the muscles of 
speech. Cerebellar syndrome deficits are usually symmetrical with all four limbs 
involved. Manifestations of cerebellar lesions are ataxia hypotonic, and truncal weakness 
causing postural endowment disorders. Dysarthria of cerebellar origin (scanning speech, 
producing a prolonged, monotone sound) is common.6 The cerebral syndrome is 
characterized by optic neuritis, the manifestation of demyelization of the optic nerve, and 
presents as a painful loss of vision. It is commonly associated with visual field defects,
8decreased color vision, and reduced clarity of vision. Although not as common as other 
symptoms, it is highly indicative of MS.
As a chronic disease, MS has a dramatic impact on quality of life (QOL). MS 
disrupts established roles in the family and society. It threatens one’s educational and 
vocational opportunities and reduces incomes. The physician may view MS is terms of 
management of a complex and interacting set of symptoms, with the goal of reducing or 
eliminating these symptoms. The therapist may view it in terms of changes in functional 
status, with the goal of improving function in activities of daily living (ADL). Although 
these perspectives are legitimate, it is clear that the individual living with MS has a 
somewhat different perspective. Growing amounts of research focused on the experience 
of MS suggests that goals of individuals with MS are global and personal. They include 
such objectives as to “fashion a life” or “to craft a life” by incorporations MS into one’s 
personal, family, and work life. From individuals living with chronic disease, focusing 
on symptoms or functional status alone does not adequately reflect the meaning of their 
experience. Taking part in meaningful activities can be viewed as a common goal that is 
important to health care providers and to individuals living with MS.8
Most studies and research of MS make reference to QOL, Kurtzke Expanded 
Disability Status Scale (EDSS), the Fatigue Severity Scale (FSS), or the Fatigue Impact 
Scale (FIS), which will be further described in the following. The EDSS is a common 
disability scale used to monitor changes in disability levels and has value in determining 
prognosis. The EDSS ranges from 0 (no impairment) to 10 (death from MS), with half­
9point levels along the way. It focuses more on mobility than on sensory, bowel and 
bladder, communicative, or cognitive impairments. For an individual, a change in EDSS 
must be at least two levels (a change in one point) to be considered significant because 
the reliability of half point changes is poor. The MS Functional Composite was created 
as a quantitative index of neurologic function. It combines the 9-hole peg test, the times 
25 foot walk, and the Paced Auditory Serial Addition Test, used as upper limb, lower 
limb, and cognitive measures. The component parts of the MS Functional Composite are 
all well validated, but as a composite measure, it has not gained universal acceptance as a 
valid outcome measure of MS impairment and disability. In the field of rehabilitation the 
EDSS remains the “gold standard” for intervention trials.6
The EDSS is very often associated with QOL in research and studies. As a 
chronic disease MS has a significant effect on QOL. MS disrupts established roles in the 
family and in society. It threatens one’s educational and vocational opportunities and 
decreases income.9 The World Health Organization (WHO) defines QOL as: “an 
individual’s perception of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectations, standards and 
concerns”, clearly demonstrating the complexity of the notion. WHO spent years using 
international experts, large scale international translation strategies and a number of pilot 
studies (including 4802 participants across 15 field studies worldwide) defining it and 
developing a tool by which to measure it. The tool it used to measure QOL is the 
WHOQOL-lOO, a 100 item questionnaire that measures six domains (physical health, 
psychological, level of independence, social relations, environment, and spiritual). The 
WHOQOL is one of the more common QOL questionnaires used along with the Multiple
10
Sclerosis Quality of Living (MSQOL) by the MS Society.2,8
Some people report experiencing a reduction in daily function somewhat similar 
to a grieving process as MS restricts many activities such as employment or social 
interactions. Coming to terms with such major changes in one’s lifestyle has the potential 
to result in an increased sense of helplessness and hopelessness, low self-esteem, 
decreased motivation and decreased QOL as poor health may reduces an individual’s 
sense of well-being. Some of the research conducted with MS populations has indicated 
that the severity of symptoms and physical disability, disturbances in role status and 
lifestyle changes have been associated with reduced QOL.10
Another commonly used scale if the Fatigue Severity Scale (FSS) and this is 
because fatigue is the most common symptom of MS with a frequency of 70% or more in 
patient surveys.1 The FSS was developed in order to differentiate individuals with MS 
and lupus from normal subjects. The scale consists of nine statements about fatigue 
symptoms to which subjects respond using a 7-point Likert scale. Scores for each 
statement are summed. With a maximum score of 63, the mean for MS individuals is 43. 
In other words, most MS individuals, in fact 91%, score above the cut-off for fatigue, 
with scores at the tip of the scale. There is some criticism of the FSS for its lack of 
sensitivity to subtle change. Another scale to measure fatigue is the Fatigue Impact Scale 
(FIS) which differentiates between physical, cognitive, and social aspects of fatigue.
This scale is much more detailed with 42 Likert-type questions.1
One survey reported 90% of their sample study to be bothered by fatigue. On both 
the fatigue severity and fatigue interference rating scales participants indicated their
11
average level of fatigue severity and interference was approximately in the middle of the 
11 point scales. The most common score on the fatigue severity scale was 7, while the 
most common score on the fatigue interference was 0. For most participants then, fatigue 
is a present and bothersome symptom, yet one that does not stop them from carrying out 
their day to day activities.1 The symptoms and results of MS which are often found to 
lead people to quit their jobs are physical difficulty, ambulation problems, visual 
difficulties, emotional problems, and fatigue.11
An exacerbation (also known as an attack, a relapse, or a flare) is a sudden 
worsening of an MS symptom or symptoms, or the appearance of new symptoms, which 
lasts at least 24 hours and is separated from a previous exacerbation by at least one 
month. The most common disease course in MS, called relapsing-remitting MS, is 
characterized by clearly defined acute exacerbations, followed by complete or partial 
recovery with no progression of the disease between attacks.1 A true exacerbation of MS 
generally last days to weeks and is caused by an area of inflammation in the central 
nervous system. This is followed by demyelination—the destruction of myelin, which is 
the fatty sheath that surrounds and protects the nerve fibers. Demyelination results in the 
formation of an abnormal area called a plaque and causes the nerve impulses to be 
slowed, distorted, or halted, producing the symptoms of MS. One example of an 
exacerbation of MS would be the development of optic neuritis, an inflammation of the 
optic nerve that impairs vision. An exacerbation may be mild or may significantly 
interfere with the individual's daily life. Exacerbations usually last from several days to 
several weeks, although they may extend into months. It is generally accepted that a short
12
course of corticosteroids will cause an exacerbation to be shorter and/or less severe.
Sometimes an increase in symptoms has nothing to do with the underlying MS, 
but is caused by factors such as fever, infection, or hot weather that can temporarily 
aggravate MS problems.1 The temporary aggravation is referred to as a 
pseudoexacerbation. Once the triggering event is past—e.g., the body temperature returns 
to normal, the symptoms subside as well. Some people with MS report a worsening of 
their symptoms during or after periods of intense stress. Researchers are exploring the 
effects of stress on the immune system and its possible involvement in MS.
A remission does not mean that all the symptoms of MS disappear, but rather that 
a person with MS returns to the baseline that existed before the last exacerbation began. 
The average frequency of attacks is approximately one a year with the attacks varying in 
severity; therefore, close surveillance is required to reliably tabulate the attack frequency. 
Attacks tend to be most common in the early years of MS and become less frequent in the 
later years, regardless of the disability. The risk for rapid development of moderate 
disabilities may be greater in persons in whom the frequency of attacks in higher than 
average. Frequent attacks are less cause for concern than the development of progressive 
MS, however.13
Data from a meta-analysis of primary and secondary outcomes in existing United 
States clinical and historical MS data sets to test the effect of relapses on development of 
disability was reviewed and investigators found that each attack carries a 42% chance of
13
adding measurable residual impairment and that the mean was an additional 0.3 EDDS 
score per attack. Residual deficits that persist for 3 months post exacerbation usually do 
not resolve. Successful clinical trials with immunomodulatory drugs have shown clear 
evidence of or a trend toward slowed an increase of impairment while consistently 
showing reduced relapse rates. These studies were all conducted in ambulatory patients 
who continued to have relapses. In contrast, a French study retrospectively studied a 
large French MS cohort and reported that relapse rates predict an increase of impairment 
only up to a point at which a mild degree of permanent disability is present (EDSS 
=4.0).' At higher levels of disability, there is a disconnection between relapses and 
progression of disability . Together these findings suggest that relapses are associated 
with worsening impairment at the early stages of disease (when inflammation is 
prominent) but probably not after marked disability has been acquired (when 
neurodegenerative changes predominate). Therefore, to have an effect on disability, 
treatment must be started early.
A confusing factor is the definition and identification of a relapse or exacerbation. 
Traditionally, a relapse is the development or a new symptom or sign of worsening of 
existing ones. However, research has indicated that patients may not be aware of many 
relapses. Frequent gadolinium-enhanced MRI scans of the brain(every 4 to 6 weeks) 
have shown 5 to 10 relapses not recognized by the MS patient.14 Initially counterintuitive 
it is likely that the disease activity in the CNS not directory involving visual, sensory, or 
motor pathways may not be appreciated as a relapse. Indeed might such activity account 
for the intermittent memory loss and mood dysfunction often experienced by patients
14
with MS? After all, most of the brains white matter does not involve visual, motor, or 
sensory pathways.1
Ultimately since the risk for rapid development of moderate disabilities 
may be greater in persons in whom the frequency of attacks in higher than average, the 
treatment must focus on avoiding of attacks. Treatments focus on slowing the 
progression of the disease by decreasing the number and severity of relapses and on 
minimizing the symptomatic problems. The most commonly experienced symptomatic 
problems in MS include fatigue, depression, spasticity, tremors, pain, bladder problems, 
bowel problems, and sexual dysfunction. Ones quality of life can be significantly 
improved if the symptomatic problems are properly addressed and treated.4
An investigation of rehabilitation usage patterns in North America was conducted 
by Hadjimichael. Using self-selected patient registry it found that 66% of 21, 330 active 
registry participants had used rehabilitation at some time and that 31% were current 
users. The most frequently used rehabilitation service was physical therapy (PT 41%), 
followed, in decreasing order, by occupational therapy (OT), psychology, massage 
therapy and social worker and speech therapy. About 13 % had received care from 
physiatrist MS specialist. As would be expected, older age, longer duration of disease, 
more reported relapses, and higher disability correlated with increased use of 
rehabilitation services. The survey showed that rehabilitation users tend to have fewer 
years of education, less income, lower rates of employment, and consequently, less 
private in insurance coverage. As people with MS tend to have the previously listed
15
qualities it makes it very important for people with MS to receive advanced, 
comprehensive, cost effective care.1 Physical Therapists need to keep in mind that they 
are the most frequently used rehabilitation and should anticipate future needs and lay the 
groundwork for services and equipment for the patients in advance. An example would 
be to encourage balance and endurance training before someone has begun to experience 
falls or fatigue.15
A common goal in MS is to maximize the individual’s physical, emotional, social, 
and vocational independence to improve QOL for them and their caregivers. Because 
MS impacts many aspects of a persons life, an individualized, multidisciplinary approach 
is essential to rehabilitation. Patient counseling may be very effective towards reducing 
attacks as long at the patient follows advice and techniques given by the PT. When 
addressing symptoms of MS one must take into account the severity of each symptom.1 
One of the leading symptoms of MS if fatigue and is defined among the MS individuals 
as “a sense of physical tiredness and lack of energy, distinct from sadness or weakness”. 
Although it is the most common symptom of MS , with a frequency of 70% or more in 
patient surveys, it was under-recognized before 2 decades ago. Over 80% who have 
fatigue report that it is exacerbated by heat, which appears to be the difference between 
MS fatigue and fatigue due to other chronic diseases. A worsening of fatigue may herald 
an MS exacerbation.1,13
16
The following example illustrates the importance of recognizing various 
perspectives on MS. A 40 year old woman with MS stumbles and falls at her place of 
work. The physician may view this scenario from the perspective of symptom 
management and seek information about leg strength and coordination along with 
complicating factors such as heat sensitivity or fatigue. A physical therapists* perspective 
/ may include functional status and question whether mobility aids are needed to maintain 
independence. The individual with MS may view this scenario from a more global and 
personal perspective and ask questions such as the following: “What do my coworkers 
think of me? Should I really be working? How can I manage financially if I can no longer 
work? What will I do if I can no longer work?” Failure to appreciate these differences in 
perspectives may be frustrating to all involved.1
Qualitative studies have provided insights into the preferences of individuals with 
MS with respect to health care decisions. It is apparent from interviewing individuals 
with MS about healthcare communication that many prefer to “take charge” of their own 
health care. One of the primary factors contributing to this preference is that individuals 
with MS believe they have the “big picture” rather than the health care providers. One 
individual summed up this outlook by saying, “The medical profession knows so 
little...it’s been clear to me since the very beginning that the ball was in my court.”2 
Differences in viewpoints between health care workers and patients can lead to the notion 
expressed by some individuals with MS that “ nobody listened”. These ideas make it 
obvious that it is critical for healthcare workers treating individuals with MS be well 
educated of MS and it’s global effects.1 The global effects of MS require a global
17
approach when treating MS. “The role of the healthcare provider is to form a partnership 
to enhance the ability of the individual with MS to take part in activities that have
o
personal value and meaning. ” It at times may be important for the healthcare worker to 
relinquish the role as the expert, as a person with MS is the expert of their case of MS.
For individuals with MS, participation is an outcome that reflects the influence 
and interaction of many factors, including the pattern and level of function and disability 
along with environmental and personal factors. Function and disability, environmental 
factors, and personal factors contribute to the level of participation. Function and 
disability is a domain that includes different types and levels of impairment and 
limitations in activity.15 For the healthcare provider, participation represents the 
convergence of many factors and may be considered a “metaoutcome” rehabilitation. 
Participation can be enhanced in many ways such as by minimizing the impairment, by 
increasing performance on important activities, by providing adequate environmental 
support, by reducing social and environmental barriers and by enhancing personal coping 
strategies.1 In a study of MS patients, it was found that approximately one fourth of the 
participants had stopped visiting friends and family members because of poor mobility 
associated with MS. As you can see, all aspects of the MS patients health are directly 
related to the patients ability to maintain their normal every day functions. Their ability 
to continue activities can definitely be associated to the high rate of depression in MS 
patients.
18
This model came from source 2.
From reviewing the above model you can really see how people with MS have 
every area of their life affected. Not only does MS often limit them from working, 
performing leisure activities and performing ADL’s, the ability or lack thereof to perform 
the previous listed tasks affects their social life and other areas of their life which then 
affects another area such as self confidence or depression level. Keeping people with MS 
as active as possible for the longest amount of time is very important for this very reason.
A comparison of the costs and benefits of activities and treatments must be 
evaluated in order for the person with MS to receive the most effective care. An example 
of an activity which must be reviewed is maintaining paid employment; employment has 
personal and financial benefits but the costs include having less time and energy for
19
things outside work. The opposite of working, “taking it easy”, is well intended, but is 
not always consistent with the goals and preference of the individual living with MS.8 
The treatments for individuals with MS such as medications or therapies must be 
evaluated for cost, side effects, and both long and short-term benefits.
A challenge faced by patients, clinicians, and researchers if determining which 
health-promotion activities are not only supported by the evidence but also appropriate 
for a given patient16 It is important to counsel a patient with MS in safety especially 
when instructing a patient in exercising. Individuals with MS often demonstrate an 
inability to sustain physical activity and have greater impairment after an elevation of 
body temperature, known as the Uhthoff phenomenon. The Uhthoff phenomenon may be 
due to an exercise associated rise in the core body temperature, which interferes with 
conduction across partly demyelinated axons. Three reviews of the literature on exercise 
physiology and MS up to the year 2001 have drawn several conclusions:
1. In mild cases of MS, muscle function is close to normal.
2. Minimal to moderate neurologic impairments of individuals with MS usually 
have preserved cardiovascular responses during exercise. An exception is that 
some individuals with MS, those whom re highly more impaired, have a blunted 
heart-rate response to increased exercise stress.
3. Degree of physical impairment influences the maximal aerobic capacity in 
persons with MS. A shorter period of exercise, an achieved lower maximal 
exercise intensity, and lower maximal oxygen uptake are present with individuals 
with more impairment.
20
4. Aerobic capacity is limited by respiratory muscle dysfunction and 
reconditioning.
5. Although improvements may be less impressive when there is more neurologic 
impairment, regular exercise have a positive affect on fitness as it does for healthy 
individuals.1
One basic exercise program to maintain or incorporate into treatment for all 
individuals with MS is “lifestyle exercise”. If a formal exercise program is not possible, 
individuals with MS should be encouraged to begin exercising by more fully participating 
in basic and advanced activities of daily living such as shopping, housework, and 
childcare. Individuals participating in this type of exercise should be taught to build 
insufficiencies into their daily life such as parking further from the supermarket or taking 
stairs rather than the elevator. The next step from “lifestyle exercise” is participating in 
active recreation such as walking, swimming, hiking, dancing, golf, or gardening.17 
These two types of exercise when looking at the cost comparison to other exercise are or 
can be relatively at no cost as they are merely incorporated into activities which would 
already have been done. When formal exercise is an option there are many choices to be 
made, depending on the needs and goals of the patient.
When taking into account the cost of therapy and drugs, therapy may be a cheaper 
route, if the patient can avoid adding more medications to their daily regime completely 
or at least delay the need of it. Not only do medications add cost to the ongoing medical 
treatment of patients, but they also add unwanted symptoms or side effects and could
21
possibly interact badly with current medications. A common bladder problem seen in 
MS patients is the failure to store urine. Physical therapists can use several treatments to 
help MS patients be able to hold their urine longer, therefore reducing or removing their 
urinary urgency problems. In some cases, the patient can do treatment option such as 
Biofeedback which helps them learn to use their pelvic floor muscles more efficiently. In 
the Biofeedback electrodes are attached to their muscles which help them to train their 
muscles to work correctly and as they need them. In cases such as this a patient can 
possibly be discharged from treatment around 4-8 treatments. After the first few 
treatments, the physical therapist will assess their improvements, assessing the level of 
improvement or lack thereof, and continue or discharge the patient as needed. There are 
several areas in symptoms that Physical Therapists can help people with MS improve 
upon or learn how to manage their tasks with the level of function they have.
For comparison, charts have been compiled which compare the price of the 
common medicines and the price for physical therapy treatment per unit. The prices 
listed may vary from location to location and from insurance company to insurance 
company. The information for the physical therapy charges is from Koke Mill Medical 
Center Rehabilitation Department in Springfield, IL and the medications and costs was 
taken from an article from the Consortium of Multiple Sclerosis Centers and was written 
by Ellen Guthrie, Pharmacist of Children’s Healthcare of Atlanta.5
Also, when reviewing the costs charts it is important to keep in mind that while at 
a physical therapy session the Physical Therapist can work towards improving several
22
symptoms such as bladder control, muscle strength, gait, coordination, etc. On the other 
hand it is very uncommon that being on one medication will improve more than one 
















Tofranil Yes $$ for generic
Ditropan XL, Oxytrol NO $$$
Detrol, Detrol LA NO $$$





Alprostadil, Papaverine, etc NO $$$$
Lubricants YES $
*$ represents $20-40/month 
$$ represents $40-60/month 
$$$ represents $60-100/month 
$$$$ represents any amount over $ 100/month
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MS never has a “one size fits all” treatment strategy and each patients treatment 
will be constantly changing with the change of the patients progression of MS. Most 
physical therapists are not specialists in MS and need to learn more about the disease in 
order to competently treat the patient’s impairments and symptoms. In order to treat 
people with MS, physical therapists should utilize all aspects of the healthcare system and 
work with a global perspective. Working with a global perspective will allow the 
Physical Therapist to forge a relationship with the patient of understanding both the 
physical therapy side to the patients impairments and symptoms but also the patient 
perspective to the impairments and symptoms.
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